Reintroducing
About us / Press room
News about our community
Our actions match our words
April 9, 2018
ORTHO DERMATOLOGICS ANNOUNCES PUBLICATION OF PIVOTAL EFFICACY AND SAFETY DATA FOR PSORIASIS TREATMENT DUOBRIITM IN THE JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

DUOBRII Demonstrated Significant Superiority Over Vehicle As Early As Two Weeks

LAVAL, Quebec, April 9, 2018 – Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC (NYSE/TSX: VRX), today announced that the Journal of the American Academy of Dermatology (JAAD) published for the first time positive results from two Phase 3, multicenter, randomized, double-blind clinical trials (Studies 1 and 2) to assess the safety and efficacy of DUOBRIITM1 (halobetasol propionate and tazarotene) (IDP-118) lotion in the treatment of plaque psoriasis.2

February 27, 2018
VALEANT ANNOUNCES LICENSING AGREEMENT WITH KAKEN PHARMACEUTICAL CO., LTD. TO DEVELOP AND COMMERCIALIZE NEW CHEMICAL ENTITY FOR PSORIASIS

LAVAL, Quebec, Feb. 27, 2018 – Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant” or the “Company”) today announced its subsidiary has entered into an exclusive license agreement with Kaken Pharmaceutical Co., Ltd., (“Kaken”) to develop and commercialize products containing a new chemical entity, KP-470, which is an investigational compound for the topical treatment of psoriasis. If approved, KP-470 will represent a novel drug with an alternate mechanism of action in the topical treatment of the disease.

February 22, 2018
ORTHO DERMATOLOGICS RECEIVES U.S. FDA APPROVAL FOR EXPANDED USE OF LUZU® (LULICONAZOLE) CREAM, 1%, IN PEDIATRIC PATIENTS WITH ATHLETE’S FOOT, JOCK ITCH AND RINGWORM

RALEIGH, N.C., FEBRUARY 22, 2018 – Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC (NYSE: VRX and TSX: VRX) (“Valeant”), today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) to expand the use of LUZU® (luliconazole) cream, 1% for the topical treatment of patients 12 and older with athlete’s foot (interdigital tinea pedis) and jock itch (tinea cruris) and patients two and older with ringworm (tinea corporis), caused by the organisms Trichophyton rubrum and Epidermophyton floccosum. These conditions are very common skin diseases caused predominantly by dermatophyte fungi.1 LUZU was initially approved as a treatment for adults in 2013.

February 14, 2018
ORTHO DERMATOLOGICS ANNOUNCES U.S. FDA FILING ACCEPTANCE FOR JEMDEL™ PLAQUE PSORIASIS TREATMENT

LAVAL, Quebec, Feb. 14, 2018 – Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”), today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application for JEMDEL™1 (halobetasol propionate 0.01%) (IDP-122) lotion with a PDUFA action date of Oct. 5, 2018. If approved, JEMDEL will be the first highpotency topical steroid treatment for plaque psoriasis with dosing for as long as eight weeks. In the clinical trials, the most common adverse event was upper respiratory tract infection.

February 13, 2018
ORTHO DERMATOLOGICS SUPPORTS STUDENTS TREATED FOR DERMATOLOGIC CONDITIONS THROUGH ASPIRE HIGHER SCHOLARSHIPS

Submission Period for Applications Open through April 28, 2018

RALEIGH, N.C., Feb. 13, 2018 – Ortho Dermatologics today announced it will begin accepting applications for the 2018 Aspire Higher scholarship program for students who have been affected by dermatologic conditions. Through the program, nine students will receive a scholarship of $10,000.

“Pursuing higher education is an extraordinary milestone in people’s lives and at Ortho Dermatologics, we understand that the journey for those living with a dermatologic condition can come with additional personal challenges,” said Bill Humphries, executive vice president and group company chairman, Ortho Dermatologics. “For that reason, we are proud to continue the Aspire Higher scholarship program and honor outstanding students who have managed the difficulties of living with a skin condition while focusing on achieving their educational goals.”

 

January 22, 2018
ORTHO DERMATOLOGICS ANNOUNCES COMMERCIAL AVAILABILITY OF RETIN-A MICRO® (TRETINOIN) GEL MICROSPHERE 0.06% TOPICAL TREATMENT FOR ACNE VULGARIS

RALEIGH, N.C., Jan. 22, 2018 – Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC (NYSE: VRX and TSX: VRX), today announced that RETIN-A MICRO® (tretinoin) gel microsphere 0.06% will be available commercially to health care professionals on January 22, 2018. The U.S. Food and Drug Administration (FDA) approved the Supplemental New Drug Application (sNDA) for RETIN-A MICRO® (tretinoin) gel microsphere 0.06% for topical application in the treatment of acne vulgaris on October 24, 2017.

January 12, 2018
ORTHO DERMATOLOGICS ANNOUNCES U.S. FDA FILING ACCEPTANCE FOR IDP-121 ACNE TREATMENT IN LOTION FORM

LAVAL, Quebec, Jan. 12, 2018 – Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) (“Valeant”) , today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application for IDP-121 (tretinoin 0.05%) lotion (ALTRENOTM1) with a PDUFA action date of Aug. 27, 2018. If approved, ALTRENO will be the first tretinoin product in lotion form rather than a gel or cream.

December 6, 2017
Scholarships Awarded to Students with Dermatologic Conditions

Scholarships were awarded to 9 recipients through the Aspire Higher Scholarship program. The winners of the program are applicants or current attendees of an accredited, nonprofit, 2- or 4-year college, university, or advanced (post-high school) vocational or technical school who have been treated for a dermatologic condition.

November 14, 2017
ORTHO DERMATOLOGICS ANNOUNCES ASPIRE HIGHER SCHOLARSHIP HONOREES

Scholarship Program Awards Students Across the Country Impacted by Dermatologic Conditions 

Raleigh, NC, November 14, 2017 – Ortho Dermatologics, one of the largest prescription dermatology healthcare businesses in the world, today announced the nine recipients of the Aspire Higher Scholarship program, which honors the achievements of applicants or current attendees of an accredited, nonprofit, two- or four-year college, university, or advanced (post-high school) vocational or technical school who have been treated for a dermatologic condition.

November 2, 2017
ORTHO DERMATOLOGICS ANNOUNCES U.S. FDA FILING ACCEPTANCE FOR IDP-118, NOVEL PLAQUE PSORIASIS TREATMENT

PDUFA Date Set for June 18, 2018

LAVAL, Quebec, Nov. 2, 2017 – Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for IDP-118 (halobetasol propionate and tazarotene) lotion, an investigational topical treatment for plaque psoriasis. The PDUFA action date is June 18, 2018.

If approved, IDP-118 will be the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation for the treatment of plaque psoriasis in adult patients, allowing for a potentially expanded duration of use.

The most common adverse events were contact dermatitis (7.4%) and application site pain (2.6%).

X
X
X